Driving prices down for much-needed medications.
More than two decades ago, a Mumbai-based 80-year-old pharmaceutical company developed a revolutionary anti-AIDS cocktail and stunned the world by offering it for as low as a dollar a day. The move may have pushed the envelope in patent law, but it proved to be a turning point in the battle against the killer disease. Today, one in three people living with HIV across 115 countries are taking a Cipla drug.
Since then, the $2 billion-in-revenue Cipla has made affordability and global accessibility to medicines the cornerstone of its business plan, reflecting the company’s vision: “None shall be denied.” Cipla has by far the world’s widest range of antiretroviral (ARV) products approved by FDA and WHO for treating both children and adults suffering from HIV/AIDS, and also offers free ARV technology to all African countries wanting to produce their own drugs. The group has done the same for malaria, with its “less than a dollar” dose, becoming one of the largest suppliers of anti-malaria drugs in the world.
Next up in Cipla’s crusade for low-cost pills: to replicate the “dollar a day” initiative in its fight against cancer. The company is investing in a drive to create “biosimilar” versions of certain pricey oncology drugs. Expect heated intellectual-property debates—and cheaper medicines.
|Revenues ($M) (Last Fiscal Year)||$2,045|
|Profits ($M) (Last Fiscal Year)||$230|
|Market Value ($M)||$6,299|